Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Behandeling stadium II-III niet-kleincellig longcarcinoom gaat flink op de schop
apr 2024 | Immuuntherapie, Longoncologie